|Therapeutic Angiotensin-(1-7) (Code C68962)|
|Terms & Properties|
Preferred Name: Therapeutic Angiotensin-(1-7)
Definition: A synthetic heptapeptide identical to endogenous angiotensin-(1-7) with vasodilator and antiproliferative activities. Therapeutic angiotensin 1-7 may inhibit cyclooxygenase 2 (COX-2) and the production of proinflammatory prostaglandins and may activate the angiotensin-(1-7) receptor Mas, resulting in diminished tumor cell proliferation. Activation of the angiotensin-(1-7) receptor Mas, a G-protein coupled, seven transmembrane protein, may down-regulate the phosphorylation and activation of Erk1 and Erk2 in the Erk1/Erk2 MAPK signaling pathway. In the renin-angiotensin system, the vasodilating activity of angiotensin- (1-7), hydrolysed from angiotensin II by the type I transmembrane metallopeptidase and carboxypeptidase angiotensin converting enzyme 2 (ACE2) in vivo, counteracts the vasoconstricting activity of angiotensin II.
NCI-GLOSS Definition: A substance being studied in the treatment of several types of cancer. Therapeutic angiotensin-(1-7) is a hormone that is made in the laboratory, and helps control blood pressure. It may stop the growth of some types of cancer cells and may stop the growth of blood vessels needed by tumors to grow. It is a type of antiproliferative agent.
Display Name: Therapeutic Angiotensin-(1-7)
Label: Therapeutic Angiotensin-(1-7)
NCI Metathesaurus Link: C0103306 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|ChEBI ID||CHEBI:55438 (see ChEBI info)|
|PDQ Closed Trial Search ID||543940|
|PDQ Open Trial Search ID||543940 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|